Healthcare Providers

To date, there have been more clade II mpox cases reported to the Virginia Department of Health this year than in all of 2023. This serves as a reminder for providers to continue to keep mpox in mind when evaluating patients and recommend JYNNEOS vaccine for people at risk. Please check the VDH mpox dashboard for the most up-to-date data.  

Clade I mpox continues to spread in Central and Eastern Africa, with spread to other countries. On November 16, 2024, the first case of clade I mpox was reported in the U.S.

For more information, please see the Important Updates section below. 

 

Important Updates

VDH Clinician Resources

Mpox screening, prevention, and treatment should be incorporated into routine sexual health and HIV services to ensure all patients are screened for mpox, assessed for risk factors, counseled on prevention measures, and evaluated for testing and treatment, if indicated.

CDC Clinician Resources

Testing

Commercial laboratory testing for mpox is available. VDH encourages providers to use commercial laboratories, but this testing is not free. The laboratories will bill private insurance, Medicaid, or Medicare for all testing performed. Providers may find the relevant CPT code for mpox virus testing on each commercial laboratory’s website. Providers who encounter any issues while trying to order testing should contact the laboratory’s client services.

Public health testing through the Division of Consolidated Laboratory Services (DCLS) continues to be available at no cost for patients who meet clinical and epidemiologic criteria, which includes clade-specific testing to distinguish clade I and clade II MPXV. Providers should consult with their LHD about clade specific testing.

Labs Conducting Testing and Supporting Information

Patient Evaluation and Education

Vaccine

Opens pdf to download

Opens document to download

Opens in a new window

External link will open in a new window.  Click link to exit Virginia Department of Health Website. 

Last Updated: December 9, 2024